Tarsus Pharmaceuticals, Inc. (TARS) Financials
TARS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 266.2 million | 69.2 million |
2023-09-30 | 268.3 million | 54.7 million |
2023-06-30 | 188.9 million | 41.2 million |
2023-03-31 | 211.2 million | 37.8 million |
TARS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -35.3 million | 5.5 million |
2023-09-30 | -36.7 million | 5.3 million |
2023-06-30 | -24.6 million | 5.2 million |
2023-03-31 | -22.3 million | 3.9 million |
TARS Net Income
No data available :(
TARS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 227.4 million | - | 398000 |
2023-09-30 | 246.9 million | - | 423000 |
2023-06-30 | 178.2 million | - | 431000 |
2023-03-31 | 201.2 million | - | 703000 |
TARS Shares Outstanding
TARS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 4.0 million | 13.3 million | 65.7 million | 22.7 million |
2023-09-30 | 4.4 million | 12.1 million | 30.3 million | - |
2023-06-30 | 787000 | 12.5 million | 20.3 million | - |
2023-03-31 | 340000 | 12.4 million | 15.1 million | - |
TARS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 13.1 million | 1.2 million |
2023-09-30 | 1.9 million | 377000 |
2023-06-30 | 15.3 million | 316000 |
2023-03-31 | 2.5 million | 255000 |
TARS
Price: $32.12
52 week price:
Earnings Per Share: -4.62 USD
P/E Ratio: -7.43
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 37491
Market Capitalization: 1.3 billion